SecBot SecBot
8-K ·Filed Mar 4, 2026

PEPG

PepGen Inc.
MIXED
Impact 6/10
Horizonweeks Processed8mo ago SEC0001193125-26-091503
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

Monitor FDA interactions closely as resolution of the partial clinical hold is critical for U.S. trial progression, while international trial sites continue enrollment. The upcoming 5 mg/kg data readout in Q1 2026 will be a key catalyst.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$5.51
T+0 close · Mar 4, 2026 · via day close
Latest settled
−73.30%
T+60 · $1.47
Vs SPY
−84.60%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 5 $5.51entry
  2. T+1 · 9mo ago +3.27%α +4.58% · $5.69
  3. T+5 · 8mo ago +11.72%α +13.95% · $6.15
  4. T+20 · 8mo ago −68.57%α −64.79% · $1.73
  5. T+60 · 6mo ago −73.30%α −84.60% · $1.47
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

PepGen reported financial results for 2025 and provided updates on its PGN-EDODM1 clinical program for myotonic dystrophy type 1. The company announced a partial clinical hold by the FDA on its FREEDOM2 trial due to preclinical pharmacology and toxicology concerns, while also highlighting positive Phase 1 data and ongoing enrollment in international sites. Financially, the company reduced its net loss year-over-year and maintains a strong cash position into 2027.

Key Financial Metrics

EPS
$-2.12

Key Facts

  • FDA placed a partial clinical hold on the FREEDOM2 Phase 2 trial due to preclinical pharmacology and toxicology data concerns
  • Positive Phase 1 FREEDOM trial data showed dose-dependent splicing correction up to 53.7% at 15 mg/kg with generally well-tolerated safety profile
  • Company expects data readouts from the 5 mg/kg cohort in Q1 2026 and 10 mg/kg cohort in 2H 2026
  • Cash position of $148.5 million as of December 31, 2025, sufficient to fund operations into the second half of 2027
  • Net loss decreased to $89.7 million in 2025 from $90.0 million in 2024

Financial Impact

Reduced net loss from $90.0M to $89.7M year-over-year with cash runway extending into 2027

net losscash positionR&D expenses

Risk Factors

  • FDA partial clinical hold could delay or prevent U.S. clinical development if not resolved
  • Safety signals at higher doses (albuminuria) could impact development path
  • Dependence on successful clinical trial outcomes for future value creation

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-091503
Document: pepg-20260304.htm0001193125-26-091503
Document: pepg-ex99_2.htm0001193125-26-091503
Document: 0001193125-26-091503-index-headers.html0001193125-26-091503
Document: 0001193125-26-091503-index.html0001193125-26-091503
Document: 0001193125-26-091503.txt0001193125-26-091503

Track record

12 reports on PEPG

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +31.95% at T+20 after the Aug 6, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Bearish 6/10 Entry $4.36 to $4.19 Now $4.19 +3.90% ▲ +3.90% +1.99% vs SPY
  2. Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $4.36 to $4.19 Now $4.19 +3.90% ▲ +3.90% +1.99% vs SPY
  3. Nov 10, 20266d ago 424B5 Bearish 6/10 Entry $5.26 to $5.04 Now $4.19 +20.34% ▲ +4.18% +3.83% vs SPY
  4. Nov 10, 20266d ago 8-K Bullish 7/10 Entry $4.61 to $5.26 Now $4.19 −9.11% ▲ +14.10% +12.78% vs SPY
  5. Aug 6, 202614w ago 8-K Bullish 7/10 Entry $2.41 to $2.85 Now $4.19 +73.86% ▲ +18.26% +17.65% vs SPY
  6. Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $1.51 to $1.47 Now $4.19 +177.48% ▼ −2.65% −3.19% vs SPY
  7. Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $1.51 to $1.47 Now $4.19 +177.48% ▼ −2.65% −3.19% vs SPY
  8. May 22, 202625w ago EFFECT Bearish 7/10 Entry $1.51 to $1.53 Now $4.19 −177.48% ▼ −1.32% −0.74% vs SPY
  9. May 19, 202625w ago S-3 Bearish 7/10 Entry $1.38 to $1.44 Now $4.19 −203.62% ▼ −4.35% −3.31% vs SPY
  10. May 12, 202626w ago 8-K Neutral 5/10 Entry $1.78 to $1.78 Now $4.19 +135.39% · 0.00% +0.00% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 4, 2026